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In a prospective, randomized trial, teicoplanin (at a 400-mg intravenous loading dose fol-
lowed by 200 mg/day intravenously or intramuscularly) was compared with flucloxacillin
(8 g/day) in patients with severe staphylococcal infections. Teicoplanin proved unsatisfac-
tory for the following reasons: (1) failures or relapses were more frequent in the teicopla-
nin group, and (2) blood levels were difficult to predict and tended to be low 24 hr after
the loading dose. Future trials with this agent should use much-higher doses.
Treating severe staphylococcal infections remains dif-
ficult. The most-widely used drugs, such as the an-
tistaphylococcal penicillins and vancomycin, are ad-
ministered intravenously several times daily and
expose patients to the dangers of prolonged intrave-
nous treatment and to the expense and discomfort
of hospitalization. Both types of drugs have side ef-
fects, such as allergic reactions for the penicillins [1]
and ototoxicity, nephrotoxicity, and neutropenia for
vancomycin [2].
Teicoplanin is a new antibiotic chemically related
to vancomycin [3]. In vitro studies show that it is
active against most gram-positive cocci at concen-
trations <1 mg/liter [4]. In vivo, it protects mice
against experimental staphylococcal septicemia [4,
5] and compares favorably with nafcillin and van-
comycin in experimentally induced endocarditis [6].
Toxicological studies of teicoplanin in animals
show a potential for nephrotoxicity at high doses but
no ototoxicity, in contrast to vancomycin (unpub-
lished data).
Studies in humans have demonstrated good toler-
ance after intravenous [7] and intramuscular [8] in-
jection and slow elimination, with a terminal half-
life of 70-100 hr [9, 10], factors suggesting that a
once-daily intramuscular injection might be an ap-
propriate and highly practical treatment schedule for
staphylococcal infections. In previous clinical trials
[11-14], teicoplanin was given at a dose of 400 mg
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(first day), followed by 200 mg/day. Reported suc-
cess rates were as high as 940/0 [11],but these studies
included soft-tissue infections. Cure rates were never
compared with those for standard treatments. On
the basis of these data we decided to compare tei-
coplanin with parenteral flucloxacillin in patients
with severe staphylococcal infections.
As suggested by the Ethics Committee of our hos-
pital (Dr. Jean Fabre), a preliminary analysis of the
results was performed after treating the first 18 pa-
tients. This analysis revealed a high failure rate in
patients treated with teicoplanin and led to the
premature termination of our study.
Patients and Methods
Patients. Patients were considered for the study
if they met at least one of the following criteria: (1)
two or more separate cultures of blood positive for
Staphylococcus aureus or for coagulase-negative
staphylococci, (2) staphylococci isolated from joints
or pleural space, or (3) a staphylococcal abscess oc-
curring in an immunocompromised host. (Im-
munosuppression was considered present if the pa-
tient had an underlying hematologic malignancy or
if he was receiving immunosuppressive therapy.)
Severe renal failure with a level of serum creati-
nine >250 umol/Iiter, age <16 years, pregnancy, and
treatment with antistaphylococcal agents for >48 hr
before randomization were criteria for exclusion.
Bacteriological data. Drug susceptibility was
toutinely estimated by disk diffusion using oxacil-
lin as the class disk for flucloxacillin [15]. Interpreta-
tive zones for susceptible organisms were ~13 mm
for oxacillin (disk charge, 1 J.1g) [15] and ~14 mm
for teicoplanin (disk charge, 30 J.1g; data available
from Lepetit Research Institute, Milano, Italy).
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Results
Table 1. Characteristics of the treatment groups.
NOTE. The numbers in parentheses are the number of pa-
tients in the indicated category after excluding the patients who
were not assessable.
* p < .05 (by Fischer's exact test) for patients treated with tei-
coplanin vs. flucloxacillin.
and it was a "bacteriologic failure" if, in addition
to clinical evidence of persistent infection, staphy-
lococci were isolated more than five days after the
start of treatment. All surviving patients were fol-
lowed up for eight weeks after the end of the treat-
ment. Outcomes in treatment groups were compared
by using Fischer's exact test [17].
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No. of patients
Mean age; range
No. immunosuppressed
No. with septicemia
No. with osteoarticular
infection
No. with internal
orthopedic device
No. with intravascular
prosthesis
No. with infected iv
catheter
No. treated with other
antistaphylococcal
drugs «3 days)
No. successfully treated
No. with unsatisfactory
outcomes*
Transient improvement
with relapse
Primary failure
Failure due to
side effect
No. not assessable
From 1 March to 31 July 1985, 55 patients who met
the study criteria were observed at our hospital. Of
these, 18 (33070) were included in the trial. Reasons
for exclusion were (1) treatment with effective an-
tistaphylococcal drugs for >48 hr before culture
results were known (31 cases), (2) staphylococcal in-
fection was suspected but not proved (2 cases), (3)
refusal of physicians (3 cases) or patients (l case) to
participate.
Randomization allotted six patients to receive tei-
coplanin and 12 to receive flucloxacillin treatment.
Two of the patients receiving flucloxacillin who
MICs and MBCs of teicoplanin were estimated
for each isolate by using a macrodilution procedure
performed in Mueller-Hinton broth [16].
Randomization and treatment regimen. Patients
with organisms susceptible to teicoplanin were asked
to give their oral consent to enter the study. The con-
sent specifically pointed out that the efficacy of tei-
coplanin in severe staphylococcal infections was as
yet unproven.
After giving consent, patients were randomized
to receive either flucloxacillin (2 g every 6 hr iv) or
teicoplanin (400 mg iv followed by 200 mg iv or im
at 24-hr intervals). Teicoplanin was provided by Dr.
S. Henauer (Merrel Dow Pharmaceuticals, Zurich,
Switzerland). Patients with a history of allergy to
penicillin and who were randomized to receive
flucloxacillin were switched to teicoplanin. No at-
tempt was made to blind the study.
Treatment lasted for at least four weeks for pa-
tients with septicemia of unknown origin or with en-
docarditis, for two weeks for patients with septice-
mia associated with a removable intravenous
catheter, and for at least six weeks for patients with
osteomyelitis or septicemia in the presence of an in-
travascular foreign body (such as an arterial Dacronf
graft or a valvular prosthesis).
Monitoring toxicity. The following routine lab-
oratory tests were done at least once a week: serum
creatinine, liver enzymes, and complete blood count.
Creatinine clearances were measured during the first
week and after treatment ended. Levels of teicopla-
nin were measured twice a week, and corresponding
bacteriostatic and bactericidal serum dilutions were
assessed at least once.
A solid-phase enzyme receptor assay was used to
determine levels of teicoplanin in serum. This assay
was developed by the Lepetit Research Institute
(Milano; .Dr. L. Cavenaghi, personal communica-
tion). It involves competition between teicoplanin in
the patient's serum and teicoplanin labeled with
horseradish peroxidase to bind to microplates coated
with D-alanine. A standard curve was established for
teicoplanin concentrations of 0.6-40 mg/liter by
diluting teicoplanin in pooled human serum. The
threshold for detecting teicoplanin is 1 mg/liter.
Clinical evaluation. The treatment was scored a
"success" if it abolished all clinical signs of infec-
tion and if all cultures became negative; it was a "clin-
ical failure" if, in the opinion of the attending phy-
sicians, persisting signs of infection or suspected side
effects necessitated a change in antibiotic therapy;
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* S = success, R = transient success followed by relapse, F
= failure, NA = not assessable.
Table 2. Comparison of the outcome and underlying
conditions of the patients treated with teicoplanin or
flucloxacillin.
Treatment,
patient no.
Teicoplanin
1
2
3
4
5
6
7
8
9
Flucloxacillin
1
2
3
4
5
6
7
8
9
Underlying conditions Outcome*
Chronic congestive heart R
failure, septic arthritis with
septicemia
Lymphoma, abscess with R
septicemia
Marrow transplant (aplastic R
anemia), sty, abscess of
the external ear canal
Post-traumatic paraplegia, NA
septicemia
Acute biliary pancreatitis, F
pancreatic abscess with
septicemia
Huntington's chorea, spondy- F
lodiscitis with septicemia
Aorto-fernoral prosthesis, F
catheter-related septicemia
Adenocarcinoma of the liver, NA
catheter-related septicemia
Lymphoma, neutropenia, in- NA
fected orthopedic device,
septicemia
Osteoarthritis, internal ortho- S
pedic device
Sideroblastic anemia, septice- S
mia of unknown origin
Spondylodiscitis with sep- S
ticemia
Osteitis, internal orthopedic S
device
Infected aorto-femoral pros- S
thesis, septicemia
Myeloma under chemo- S
therapy, catheter-related
septicemia
Cardiopulmonary insuffi- S
ciency, chronic lymphatic
leukemia, infected hip
prosthesis with septicemia
Drug addict, cutaneous ab- S
scesses, arthritis with
septicemia
Korsakov's syndrome, R
septicemia, osteoarthritis
The characteristics of the two treatment groups
are compared in table 1. Differences in the patient
groups, except for those related to the outcome, were
not significant (Fisher's exact test). The treatment
outcome and underlying conditions of individual pa-
tients are summarized in table 2. (Further details
about the case histories are available from the
authors.)
Table 3 summarizes bacteriologic and pharmaco-
logical data from all of the patients treated with tei-
coplanin. Trough serum levels tended to be low «10
x MIC) on the second day after starting treatment
(see patients 1,2,4, 5, 6, 7, and 9) but rose later on.
The serum levels reached with our standard regimen
of teicoplanin (see Patients and Methods) were un-
predictable. The serum levels24 hr after the teicopla-
nin loading dose (400 mg) varied from 1 to 12mg/li-
ter and reached values between 3.1 and 23 mg/liter
1 hr after the second dose (200 mg).
Injections were well tolerated, with no drop in
blood pressure. Transient neutropenia in one patient
was the only side effect observed. This patient's
blood cell count was 7,800/mm3 (85070 neutrophils,
5070 band forms, 7070 lymphocytes) before treatment
and decreased to 2,300/mm3 (31070 neutrophils, 14070
band forms, 38070 lymphocytes) after seven days of
treatment. The count improved after replacing
teichoplanin with vancomycin.
Discussion
In this small trial, patients with severe staphylococ-
cal infections that were treated with teicoplanin fared
Table 3. Pharmacological and bacteriologic data.
Levels of teicoplanin
(mg/liter)
2nd day
Patient no. MICs (mg/liter) Peak Trough Other days*
1 0.5 3.1 2.5 3.85
2 0.5 18.0 4.0 14.3
3 0.3 23.0 12.0 22.1
4 1.25 13.0 3.0 21.0
5t 10.0 9.0 1.0 7.9
6 2.5 4.8 1.2 7.7
7 0.62 4.1 4.0 7.9
8 0.62 2.2 ND ND
9t 1.25 -10.0:1: 11.5 3.5 19.7
reported a history of allergy to penicillin and one
who was infected with a methicillin-resistant,
coagulase-negative Staphylococcus were switched to
teicoplanin.
NOTE. ND = not determined.
* Arithmetic mean between the peak and trough levels.
t Infected with coagulase-negative staphylococci.
:I: Four different strains were isolated from cultures of blood
in this patient; only extreme MICs are given.
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poorly, in contrast to patients treated with fluclox-
acillin. This result, which reached statistical sig-
nificance after only 18 patients had been evaluated,
was a considerable surprise because in vitro and in
vivo studies with this new antistaphylococcal agent
had been so promising [3]. What were the reasons
that might explain this failure?
Risk factors. Patients treated with teicoplanin,
but not those treated with flucloxacillin, may have
had risk factors associated with the failure of an-
tistaphylococcal drugs. Analyzing factors such as im-
munosuppression and the presence of intravascular
foreign bodies did not, however, reveal any obvious
differences between the two treatment groups (table
1).
In both groups, risk factors associated with treat-
ment failures were frequent, and it is perhaps sur-
prising that all patients treated with flucloxacillin
responded favorably. Although relapses may still oc-
cur after the eight-week cutoff point, we are not
aware of the development of any unfavorable long-
term effects in any of our patients.
Resistance ofstaphylococci to teicoplanin. Pa-
tients were only treated with teicoplanin if the disk-
susceptibility assays showed an inhibition diameter
of at least 14 mm.This diameter corresponds to a
mean inhibitory concentration of "-'3 mg/liter, ac-
cording to the manufacturer's regression graph on
the package insert. Despite large inhibition zones,
the MICs for some coagulase-negative staphylococci
in the study were >10 mg/liter (as measured by tube
dilution [15]), as shown in table 3. In the two pa-
tients with resistant, coagulase-negative staphylococ-
ci, however, there was little clinical evidence of un-
controlled infection. The MICs for one of the
S. aureus strains was 1.25 mg/liter and another, 2.5
mg/liter. These are among the highest MICs reported
in the literature; combined with low serum levels, this
relative resistance may have contributed to treatment
failure.
Insufficient dose and insufficient serum levels of
teicoplanin. Our patients were treated with a 400-
mg loading dose and a 200-mg daily-maintenance
dose, as were patients in almost all previously
reported trials of teicoplanin [11-14].
Table 3 shows wide variations in serum drug lev-
els. Twenty-four hours after the standard loading
dose of 400 mg, serum levels varied between 1.0 and
12.0 mg/liter. Unpredictable serum levels may neces-
sitate frequent monitoring, which could offset the
ease of administering teicoplanin. Mean serum lev-
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els on the second day of treatment tended to be low
«10 x MIC) in patients 1, 4, 5, 6, 7, and 9. Low
serum levels early in treatment may contribute to
drug failure, as has been shown for aminoglycosides
[18]. Some of our patients, however, relapsed despite
high serum levels that were maintained for several
weeks, notably patients 2 and 3.
Data on the tissue distribution of teicoplanin are
still scarce. Experiments in animals have shown a
good extravascular diffusion after intravenous injec-
tion, despite high binding to serum proteins [19]. It
has been suggested, however, that protein binding
might impair the efficacy of antistaphylococcal
drugs, as observed with the new long-acting cepha-
losporin cefonicid [20]. Possibly, levels in some tis-
sues or inflammatory foci may be even lower than
those in serum.
Our results conflict with those of other investiga-
tors who have reported a success rate of up to 80070
with teicoplanin [11, 14]. The conflict may be more
apparent than real. The majority of patients treated
in other studies suffered from superficial infections,
in which it is questionable whether an antibiotic is
needed at all [21]. In one reported trial with severely
ill patients [12], only four of eight patients with bone
or joint infections, two of three patients with en-
docarditis, none of two patients with mediastinitis,
and four of 10 patients with septicemia were cured.
Future trials should use much-higher initial doses
of teicoplanin (>800 mg) to rapidly attain serum lev-
els >15 mg/liter. It remains to be determined whether
such a high dose is effective in treating severe
staphylococcal infections and whether an advantage
in toxicity remains, if compared with traditional
treatment.
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